| |
Factors associated with MVC prescription
|
|---|
|
Univariate
|
Multivariate
|
|---|
|
OR (CI 95%)
|
p
|
OR (CI 95%)
|
p
|
|---|
|
Period of test:
|
|
Before 2011
|
4.16 (2.51–6.89)
|
< 0.01
|
3.65 (2.17–6.13)
|
< 0.01
|
|
After 2011
|
1
| |
1
| |
|
Age (years):
| |
0.26
| | |
|
< 35
|
0.60 (0.25–1.45)
| | | |
|
35–43
|
0.68 (0.35–1.32)
| | | |
|
44–51
|
1.1 (0.63–1.93)
| | | |
|
> 51
|
1
| | | |
|
Time between ART initiation and tropism (years):
| |
0.03
| | |
|
< 5
|
0.50 (0.27–0.92)
| | | |
|
5–10
|
0.88 (0.49–1.58)
| | | |
|
> 10
|
1
| | | |
|
Number of previous ART regimens:
| |
< 0.01
| | |
|
< 4
|
0.24 (0.11–0.51)
| |
0.34 (0.15–0.74)
|
< 0.01
|
|
4–5
|
0.25 (0.11–0.55)
| |
0.32 (0.14–0.74)
|
< 0.01
|
|
6–10
|
0.39 (0.19–0.79)
| |
0.46 (0.22–0.97)
|
0.04
|
|
> 10
|
1
| |
1
| |
|
CD4 count (/mm3):
| |
0.02
| | |
|
≤200
|
0.34 (0.13–0.85)
| | | |
|
201–500
|
0.86 (0.52–1.42)
| | | |
|
> 500
|
1
| | | |
|
Reason for tropism performance:
| | | | |
|
Virological failure
|
1.95 (1.20–3.16)
|
< 0.01
|
1.10 (0.62–1.98)
|
0.73
|
|
Other
|
1
| |
1
| |
- MVC Maraviroc, ART Anti Retroviral Therapy
